KISQALI – ribociclib 200 mg/day (200 mg x 1) tablet

KISQALI – ribociclib 400 mg/day (200 mg x 2) tablets

KISQALI – ribociclib 600 mg/day (200 mg x 3) tablets

Novartis Pharmaceuticals Corp

HR-positive, HER2-negative early-stage breast cancer; HR-positive, HER2-negative early-stage breast cancer; HR-positive, HER2-negative advanced breast cancer; HR-positive, HER2-negative advanced breast cancer

Fridge (2-8°C)